24958-44-9

Usage

Uses

Used in Pharmaceutical Development:
2-Bromo-5-hydroxy-N-(4-hydroxyphenethyl)-4-methoxy-N-methylbenzamide is used as a potential pharmaceutical drug candidate for its potential biological activity. Its unique structure and properties make it a promising candidate for the development of new drugs targeting various diseases and conditions.
Used in Research and Development:
In the field of research, 2-Bromo-5-hydroxy-N-(4-hydroxyphenethyl)-4-methoxy-N-methylbenzamide serves as a valuable tool for studying specific biological processes. Its potential pharmacological properties and biological activity provide insights into the mechanisms of action and possible applications in understanding and treating various diseases.
Used in Drug Discovery:
2-Bromo-5-hydroxy-N-(4-hydroxyphenethyl)-4-methoxy-N-methylbenzamide is utilized in drug discovery as a lead compound. Its unique chemical structure and potential biological activity make it a valuable starting point for the design and synthesis of new drugs with improved efficacy and selectivity.
Used in Medicinal Chemistry:
In medicinal chemistry, 2-Bromo-5-hydroxy-N-(4-hydroxyphenethyl)-4-methoxy-N-methylbenzamide is employed as a template for the development of novel chemical entities. Its structural features and potential pharmacological properties guide the design and optimization of new compounds with enhanced therapeutic potential.
Used in Drug Synthesis:
2-Bromo-5-hydroxy-N-(4-hydroxyphenethyl)-4-methoxy-N-methylbenzamide is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and functional groups facilitate the development of new drugs with improved pharmacokinetic and pharmacodynamic properties.
Used in Drug Design:
In the field of drug design, 2-Bromo-5-hydroxy-N-(4-hydroxyphenethyl)-4-methoxy-N-methylbenzamide serves as a structural template for the creation of new drug candidates. Its potential biological activity and pharmacological properties inform the design of novel compounds with optimized therapeutic profiles.
Used in Drug Screening:
2-Bromo-5-hydroxy-N-(4-hydroxyphenethyl)-4-methoxy-N-methylbenzamide is employed in drug screening assays to identify potential drug candidates with specific biological activities. Its unique chemical structure and potential pharmacological properties make it a valuable tool for the discovery of new therapeutic agents.
Used in Drug Testing:
In drug testing, 2-Bromo-5-hydroxy-N-(4-hydroxyphenethyl)-4-methoxy-N-methylbenzamide is utilized to evaluate the safety, efficacy, and pharmacokinetic properties of new drug candidates. Its potential biological activity and pharmacological properties provide valuable information for the assessment of new therapeutic agents.
Used in Drug Formulation:
2-Bromo-5-hydroxy-N-(4-hydroxyphenethyl)-4-methoxy-N-methylbenzamide is used in drug formulation to develop pharmaceutical products with improved stability, solubility, and bioavailability. Its unique chemical structure and potential pharmacological properties contribute to the development of innovative drug delivery systems.
Used in Drug Manufacturing:
In the pharmaceutical industry, 2-Bromo-5-hydroxy-N-(4-hydroxyphenethyl)-4-methoxy-N-methylbenzamide is employed in the manufacturing process of new drugs. Its potential biological activity and pharmacological properties guide the production of safe and effective therapeutic agents.

Upstream product

• 72785-27-4 2-bromo-4-methoxy-5-(4-methoxybenzyloxy)-N-<2-(4-methoxybenzyloxyphenyl)ethyl>-N-methylbenzamide 
• 61186-07-0 N-methyl-N-(2-[4-hydroxyphenyl]ethyl)amine hydrobromide 
• 370-98-9 N-methyltyramine 
• 24958-43-8 5-benzyloxy-N-[2-(4-benzyloxy-phenyl)-ethyl]-2-bromo-4-methoxy-N-methylbenzamide 
• 76968-91-7 4-((4-methoxy)benzyloxy)phenylacetic acid 
• 621-59-0 isovanillin 
• 72785-25-2 2-(4-methoxybenzyloxyphenyl)-ethyl-N-methylamine 
• 72785-26-3 2-bromo-4-methoxy-5-(4-methoxybenzyloxy)-benzoic acid 
• 125145-47-3 4-methoxy-5-(4-methoxybenzyloxy)benzyl alcohol 
• 72785-29-6 4-methoxy-3-((4-methoxybenzyl)oxy)benzaldehyde 
• 125145-46-2 4-(4-methoxybenzyloxy)-phenyl-N-methylthioacetamide 
• 125145-45-1 4-(4-methoxybenzyloxy)-phenyl-N-methylacetamide 
• 1026005-61-7 [4-(4-Methoxy-benzyloxy)-phenyl]-acetyl chloride 
• 72785-28-5 4-methoxy-5-(4-methoxybenzyloxy)-benzyl acetate 

Downstream Products

• 24997-76-0 C₁₇H₁₆BrNO₄ 
• 261961-56-2 4a,5,9,10,11,12-hexahydro-1-bromo-3-methoxy-11-methyl-6H-12-oxobenzofuro[3a,3,2,-ef][2]-benzazepin-6-one 
• 357-70-0 galanthamine 
• 125145-52-0 C₁₇H₁₈BrNO₄ 
• 1668-85-5 (-)-epigalanthamine 
• 23173-11-7 rac-8-bromo-6-methoxy-10-methyl-galantham-1-ene-3,9-dione 

Relevant academic research and scientific papers

Process for making galantamine

A novel process for the preparation of N-methyl-N-(2-[4-hydroxyphenyl]ethyl)-5-hydroxy-4-methoxy benzene carboxamide, which is useful as an intermediate in the synthesis of (?)-galantamine, comprises the reaction of a 5-hydroxy-4-methoxy benzoic acid derivative with N-methyl-N-(2-[4-hydroxyphenyl]ethyl)amine.

Alternative total synthesis of (-)-galanthamine hydrobromide

An alternative total synthesis of (-)-galanthamine (1) hydrobromide, employing ecofriendly amidation, oxidative coupling, and classical resolution strategies is accomplished. Copyright Taylor & Francis Group, LLC.

Syntheses and Preparations of Narwedine and Related Novel Compounds

The present invention relates to a process for preparing racemic narwedine (which can be can be kinetically resolved) to yield (?)-narwedine and which is the biogenic precursor of (?)-galanthamine) and the use thereof as a starting material for producing (?)-galanthamine. The invention further includes processes for preparing (?)-galanthamine and (?)-galanthamine hydrobromide, as well as related novel compounds.

PROCESS FOR PREPARATION OF BENZAZEPINE

This invention discloses a process for manufacture of galanthamine, which involves a stereoselective reduction step to get the desired isomer of galanthamine. The current embodiment also discusses the method for improving the chiral and chemical purity of galanthamine and galanthamine salts.

Preparation of (-)-galantamine hydrobromide

A process for preparing (?)-galantamine hydrobromide.

Processes for the preparation of derivatives of 4a, 5, 9, 10, 11, 12-hexahydro-6H-benzofuro-[3a, 3, 2-ef][2]benzazepine

The invention relates to processes for the preparation of 4a,5,9,10,11,12-hexahydro-6H-benzofuro[3a,3,2-ef][2]benzazepine, or derivatives thereof. Furthermore, the invention also relates to the compounds formed during the preparation of 4a, 5,9,10,11,12-hexahydro-6H-benzofuro[3a,3,2-ef][2]benzazepine.

Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2]benzazepine

The invention relates to processes for the preparation of 4a,5,9,10,11,12-hexahydro-6H-benzofuro(3a,3,2-ef)(2)benzazepine, or derivatives thereof. Furthermore, the invention also relates to the compounds formed during the preparation of 4a,5,9,10,11,12-hexahydro-6H-benzofuro(3a,3,2-ef)(2)benzazepine.

SYNTHESIS OF GALANTHAMINE AND RELATED ALKALOIDS - NEW APPROARCHES. I.

Modifications of protecting groups and of the oxidative coupling conditions led to pure crystalline intermediates in the synthesis of galanthamine derivatives and gave dienone A in better yields than reported before.The E-configuration of amide 3' in crystalline state has been determined by X-ray diffraction.Streptomyces affinis 6737 reduces A to the optically active (-)-epigalanthamine derivative C, whose absolute configuration was determined by Bijvoet's method.Nematospora corylii CBS 2608 reduces to racemic B.With Ashbya gossypii IFO 1355 a mixture of racemic B and of optically active C is obtained.Some other microbial transformations are described.